Targeting CXCR4 in AML and all
D Cancilla, MP Rettig, JF DiPersio - Frontiers in oncology, 2020 - frontiersin.org
The interaction of acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL)
blasts with the bone marrow microenvironment regulates self-renewal, growth signaling, as …
blasts with the bone marrow microenvironment regulates self-renewal, growth signaling, as …
Chronic myeloid leukemia stem cells: targeting therapeutic implications
Chronic myeloid leukemia (CML) is a clonal myeloproliferative neoplasm driven by BCR-
ABL1 oncoprotein, which plays a pivotal role in CML pathology, diagnosis, and treatment as …
ABL1 oncoprotein, which plays a pivotal role in CML pathology, diagnosis, and treatment as …
Uncovering expression signatures of synergistic drug responses via ensembles of explainable machine-learning models
Abstract Machine learning may aid the choice of optimal combinations of anticancer drugs
by explaining the molecular basis of their synergy. By combining accurate models with …
by explaining the molecular basis of their synergy. By combining accurate models with …
IL-33–ST2 signaling promotes stemness in subtypes of myeloid leukemia cells through the Wnt and Notch pathways
P Naef, R Radpour, CA Jaeger-Ruckstuhl… - Science …, 2023 - science.org
Cell stemness is characterized by quiescence, pluripotency, and long-term self-renewal
capacity. Therapy-resistant leukemic stem cells (LSCs) are the primary cause of relapse in …
capacity. Therapy-resistant leukemic stem cells (LSCs) are the primary cause of relapse in …
[HTML][HTML] PRL2 inhibition elevates PTEN protein and ameliorates progression of acute myeloid leukemia
Overexpression of phosphatases of regenerating liver 2 (PRL2), detected in numerous
diverse cancers, is often associated with increased severity and poor patient prognosis …
diverse cancers, is often associated with increased severity and poor patient prognosis …
The role of inflammation in the initiation and progression of myeloid neoplasms
Myeloid malignancies are devastating hematologic cancers with limited therapeutic options.
Inflammation is emerging as a novel driver of myeloid malignancy, with important …
Inflammation is emerging as a novel driver of myeloid malignancy, with important …
Wnt signaling in leukemia and its bone marrow microenvironment
Leukemia is an aggressive hematologic neoplastic disease. Therapy-resistant leukemic
stem cells (LSCs) may contribute to the relapse of the disease. LSCs are thought to be …
stem cells (LSCs) may contribute to the relapse of the disease. LSCs are thought to be …
Theragnostic strategies harnessing the self-renewal pathways of stem-like cells in the acute myeloid leukemia
R Bhattacharjee, S Ghosh, A Nath, A Basu… - Critical reviews in …, 2022 - Elsevier
Acute myelogenous leukemia (AML) is a genetically heterogeneous and aggressive cancer
of the Hematopoietic Stem/progenitor cells. It is distinguished by the uncontrollable clonal …
of the Hematopoietic Stem/progenitor cells. It is distinguished by the uncontrollable clonal …
Antibody therapies for the treatment of acute myeloid leukemia: exploring current and emerging therapeutic targets
Introduction Acute myeloid leukemia (AML) is the most common and deadly type of leukemia
affecting adults. It is typically managed with rounds of non-targeted chemotherapy followed …
affecting adults. It is typically managed with rounds of non-targeted chemotherapy followed …
[HTML][HTML] Unveiling T cell evasion mechanisms to immune checkpoint inhibitors in acute myeloid leukemia
L Gurska, K Gritsman - Cancer Drug Resistance, 2023 - ncbi.nlm.nih.gov
Acute myeloid leukemia (AML) is a heterogeneous and aggressive hematologic malignancy
that is associated with a high relapse rate and poor prognosis. Despite advances in …
that is associated with a high relapse rate and poor prognosis. Despite advances in …